ADARx Pharmaceuticals

If successful, onvuzosiran’s rare-disease positioning and long-interval dosing could command strong pricing and share, yet HAE prophylaxis already includes Takhzyro, Orladeyo, Andembry and the RNA-targeted donidalorsen.

Payer leverage rises when multiple options exist, so differentiation must be clinically material on attack-free rates, safety and dosing simplicity. In complement diseases, Factor B already has iptacopan with broad labels, so agazisiran needs either superior efficacy, safety or dosing convenience to extract premium pricing.

ADX-626 in thrombosis competes with large anticoagulation markets and several FXI mechanisms in development. Pricing potential is meaningful but far from untapped monopolistic power.